TME Pharma Highlights NOX-A12 Research at Upcoming Conference

Author: Kelly Martin Updated: 09-19-2024 03:29 AM

TME Pharma Highlights NOX-A12 Research at Upcoming Conference

BERLIN -- TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company dedicated to discovering innovative therapies for cancer, has made an exciting announcement. An abstract showcasing crucial NOX-A12 data from preclinical studies conducted by the U.S. National Cancer Institute (NCI) has been chosen for presentation at the 2024 Society for Neuro-Oncology (SNO) Annual Meeting.

Event Overview

The SNO Annual Meeting, recognized as the largest neuro-oncology conference worldwide, attracts a diverse global attendee list from over 40 countries, including leading researchers and clinician scientists. This prestigious gathering serves as a key platform for sharing the latest knowledge and insights in neuro-oncology research and treatment. TME Pharma is set to actively participate and engage with industry leaders during the event, slated to take place from November 21-24, 2024.

Poster Presentation Details

During the meeting, a poster presentation will delve into research titled: Potentiating the efficacy of immune check-point inhibitors in glioblastoma by inhibition of CXCL12. The poster will be presented by Dr. Chen Cam-El Makranz, a Neuro-Oncology Research Fellow at the NCI.

Here are the presentation specifics:

Session: Poster Session, Poster number EXTH12
Date and Time: 7:30-9:30 PM CDT, Friday, November 22, 2024

The complete abstract is expected to be published in the SNO’s official journal, Neuro-Oncology, on November 11, 2024, with the materials made accessible on the TME Pharma website post-conference.

About NOX-A12

NOX-A12 is a unique CXCL12 inhibitor developed by TME Pharma, specifically targeting the tumor microenvironment (TME). This innovative therapeutic is designed to combat aggressive forms of cancer, including glioblastoma—a deadly brain tumor. The research surrounding NOX-A12 aims to enhance the effectiveness of existing treatment protocols by neutralizing tumor defenses and improving responses to therapies.

Clinical Trials and Achievements

TME Pharma's ongoing GLORIA Phase 1/2 trial investigates NOX-A12 in newly diagnosed brain cancer patients who may not respond well to standard chemotherapy. Top-line results from NOX-A12’s combination studies with radiotherapy indicate promising tumor reductions and responses. Additional arms of the trial are exploring NOX-A12's safety and efficacy when combined with various other treatments, aiming to identify the most effective therapeutic options for patients.

Furthermore, TME Pharma has received FDA fast-track designation for NOX-A12 in combination with radiotherapy and bevacizumab for glioblastoma treatment. This designation underlines the company’s commitment to advancing care for patients suffering from this challenging cancer.

About TME Pharma

TME Pharma’s innovative approach focuses on altering the cancer immunity cycle through its oncology pipeline. By disrupting the tumor's protective mechanisms, the company aims to enhance immune responses and treatment outcomes. Moreover, the company is also exploring additional drug candidates, including NOX-E36, aimed at targeting the innate immune system for treating various solid tumors.

Looking Ahead

As TME Pharma prepares for the SNO Annual Meeting, the company continues to strengthen its clinical initiatives and collaborations. Their partnership with MSD/Merck aims to advance research on NOX-A12 in combination with existing therapies for patients battling metastatic pancreatic cancer.

This blend of research and collaboration highlights TME Pharma's unwavering commitment to pushing the boundaries of cancer treatment. With ongoing studies and presentations at prominent conferences, they remain dedicated to discovering new avenues for enhanced therapy.

Frequently Asked Questions

What is the main focus of TME Pharma?

TME Pharma is dedicated to developing novel therapies that target the tumor microenvironment to treat aggressive cancers.

What is NOX-A12?

NOX-A12 is a CXCL12 inhibitor intended to enhance the effectiveness of existing cancer treatments by targeting the tumor microenvironment.

Where will the SNO Annual Meeting take place?

The SNO Annual Meeting will occur from November 21-24, 2024, at a location in Houston.

Who is presenting the poster at the SNO Annual Meeting?

Dr. Chen Cam-El Makranz, a Neuro-Oncology Research Fellow from the NCI, will present the poster on NOX-A12.

What is the significance of the FDA fast-track designation for NOX-A12?

The FDA fast-track designation expedites the development and review process for NOX-A12 as a promising treatment for glioblastoma.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.

TME Pharma Highlights NOX-A12 Research at Upcoming Conference